Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NMR vs IX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

IX Overall Winner 6-Pillar Tally: NMR 2 – 3 IX (1 Tie) Matrix Metrics: NMR 3 – 7 IX

As of Nov 17, 2026, ORIX Corporation (IX) is the stronger overall head-to-head candidate over Nomura Holdings, Inc (NMR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). NMR carries a Unified Composite Score of 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin), whereas IX carries 47.5/100 (HOLD) at $33.19 (12.4x Forward P/E, 20.5% operating margin).

  • Growth vs. Quality Trade-Off: IX earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. NMR 44.5/100 HOLD) and 0.98β · 27% Vol risk profile, whereas NMR leads top-line expansion (+17.9% YoY revenue growth, 0.81x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile IX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMR vs IX
NMR NYSE
Nomura Holdings, Inc
Security Brokers, Dealers & Flotation Companies
$9.34
-1.74% 1D
Market Cap $28.3B
TTM Revenue $14.9B
Forward P/E 12.7x
Beta / 30D Vol 1.03β · 29% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 47.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $9.40 · SMA50: $9.68
IX NYSE Head-to-Head Winner
ORIX Corporation American Depositary Shares (each representing One (1) Share of Common Stock)
Miscellaneous Business Credit Institution
$33.19
-1.31% 1D
Market Cap $36.9B
TTM Revenue $19.8B
Forward P/E 12.4x
Beta / 30D Vol 0.98β · 27% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 52.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.0%), weak momentum, RSI 33
RSI-14: 32.8 · SMA20: $35.57 · SMA50: $37.11

6-Pillar Scorecard Institutional Category Breakdown (NMR 2 – 3 IX)

Columns: Metric · NMR · IX
1. Valuation Multiples IX
Forward P/E 12.7x 12.4x
Trailing P/E 11.2x 6.3x
PEG Ratio 0.81x 2.72x
EV / Revenue 1.9x 1.9x
2. Growth & Scale IX
Revenue Growth (YoY) +17.9% +2.1%
Earnings Growth (YoY) +13.6% +263.3%
TTM Revenue (USD) $14.9B $19.8B
Market Cap $28.3B $36.9B
3. Profitability & Quality NMR
Gross Margin 77.4% 44.2%
Operating Margin 25.1% 20.5%
Net Profit Margin 17.1% 29.7%
Return on Equity (ROE) 11.5% 19.7%
4. Balance Sheet & Cash Flow IX
Cash Generation (TTM) N/A $6.46B EBITDA
Cash Flow Margin N/A 32.7% EBITDA Mgn
Net Cash / Leverage $8.17 Book/Sh · 11.5% ROE $29.83 Book/Sh · 19.7% ROE
Dividend Yield 3.34% 2.87%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 30.7% (<1st %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat NMR
OpEx & R&D Intensity 52.3% of Rev ($7.77B) 23.7% of Rev ($4.69B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Capital Markets Operator Financial Conglomerates Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMR (3) vs IX (7)
Institutional Metric NMR IX Criterion Row Edge
Market Capitalization
Scale
$28.3B $36.9B Larger Scale IX
Trailing P/E Ratio
Valuation
11.2x 6.3x Lower Multiple IX
Forward P/E Ratio
Valuation
12.7x 12.4x Lower Multiple IX
Revenue Growth (YoY)
Growth
+17.9% +2.1% Higher Growth NMR
Operating Margin (TTM)
Profitability
25.1% 20.5% Higher Margin NMR
Net Profit Margin
Profitability
17.1% 29.7% Higher Margin IX
Return on Equity (ROE)
Capital Efficiency
11.5% 19.7% Higher ROE IX
52-Week Range Position
Momentum
60% ($7–$11) 46% ($25–$42) Stronger Trend NMR
Beta / 30D Volatility
Risk Regime
1.03β · 29% Vol 0.98β · 27% Vol Lower Realized Risk IX
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 47.5 / 100 (HOLD) Higher Composite IX
Trailing 12M Revenue (USD)
Operating Scale
$14.9B $19.8B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.4% 44.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 1.9x EV/Rev 2.72x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.17 Book/Sh · 11.5% ROE) $6.46B EBITDA ($29.83 Book/Sh · 19.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NMR +11.48 pp
NMR: +2.36% · IX: -9.12%
3M Horizon NMR +9.68 pp
NMR: -1.84% · IX: -11.52%
6M Horizon NMR +27.52 pp
NMR: +16.69% · IX: -10.83%
1Y Horizon IX +0.21 pp
NMR: +26.32% · IX: +26.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NMR vs IX. Trailing 12-month operating profitability (NMR 25.1% vs IX 20.5%) and valuation multiples (NMR 12.7x vs IX 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.

NMR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.9B
Gross Margin77.4%
Op. Margin25.1%
ROE / Fwd P/E11.5% · 12.7x
IX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19.8B
Gross Margin44.2%
Op. Margin20.5%
ROE / Fwd P/E19.7% · 12.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.7%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMR Moat Profile Scale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $28.3B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($7.77B)
90D Engineering Disclosures 0 Published
IX Moat Profile Scale & Operating Efficiency Moat
Financial Conglomerates Operator
Competes within the Financial Conglomerates value chain with $36.9B market capitalization and 20.5% operating margin.
OpEx & R&D Reinvestment 23.7% of Rev ($4.69B)
90D Engineering Disclosures 0 Published

Investor FAQ NMR vs IX Key Questions & Quantitative Answers

As of Nov 17, 2026, ORIX Corporation (IX) is the stronger overall head-to-head candidate over Nomura Holdings, Inc (NMR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). NMR carries a Unified Composite Score of 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin), whereas IX carries 47.5/100 (HOLD) at $33.19 (12.4x Forward P/E, 20.5% operating margin). Growth vs. Quality Trade-Off: IX earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. NMR 44.5/100 HOLD) and 0.98β · 27% Vol risk profile, whereas NMR leads top-line expansion (+17.9% YoY revenue growth, 0.81x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile IX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IX leads the Growth & Scale pillar: NMR posts +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin), compared with IX at +2.1% YoY revenue growth and +263.3% YoY earnings growth on $19.8B TTM revenue (44.2% gross margin, 20.5% operating margin). On trailing 12-month operating scale, NMR generates $14.9B in USD-normalized revenue versus $19.8B for IX. In operating R&D and SG&A reinvestment, NMR deploys 52.3% of Rev ($7.77B) (0 90-day corporate R&D disclosures) versus 23.7% of Rev ($4.69B) (0 disclosures) for IX.

IX screens cheaper on headline valuation multiples. NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin), whereas IX trades at 12.4x Forward P/E, 6.3x Trailing P/E, 2.72x PEG, and 1.9x EV/Revenue (32.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMR (11.5% ROE) versus IX (19.7% ROE) capital efficiency.

In options market volatility and institutional positioning, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk). By comparison, IX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.